Zuranolone in postpartum depression: a profile of its use in the USA

Declarations

Funding The preparation of this review was not supported by any external funding.

Authorship and conflict of interest Hannah A. Blair is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability Not applicable.

Additional information about this Adis Drug Review can be found here. 

Abstract Zuranolone (ZURZUVAE®), an orally bioavailable neuroactive steroid and a selective, positive, allosteric modulator of both synaptic and extrasynaptic gamma aminobutyric acid A (GABAA) receptors, may represent a valuable treatment option for adults with postpartum depression (PPD). Zuranolone is the first oral drug to be approved for the treatment of PPD in adults in the USA. In two randomized, double-blind, placebo-controlled, phase 3 trials, a 14-day treatment course of zuranolone 50 mg (recommended dose) or 30 mg (approximately equivalent to 40 mg of approved formulation of zuranolone) once daily in the evening with food demonstrated rapid, sustained, and clinically meaningful improvements in depressive symptoms compared with placebo in adults with PPD. Improvements in symptoms of anxiety and insomnia along with beneficial effects on patient-reported functional health and well-being were observed in patients treated with zuranolone. Zuranolone was generally well tolerated. Most treatment-emergent adverse events reported in clinical trials were mild to moderate in severity, with somnolence being the most common adverse event. Zuranolone carries a boxed warning regarding driving impairment for ≥ 12 h after each dose due to its CNS depressant effects.

© Springer Nature Switzerland AG 2024